pentamethylmonomethylolmelamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 152134 |
| SCHEMBL ID | 1309901 |
| MeSH ID | M0081979 |
| Synonym |
|---|
| n-methylolpentamethylmelamine |
| ((4,6-bis(dimethylamino)-s-triazin-2-yl)methylamino)methanol |
| (hydroxymethyl)pentamethylmelamine |
| ai3-60325 |
| brn 0798740 |
| methanol, ((4,6-bis(dimethylamino)-1,3,5-triazin-2-yl)methylamino)- |
| ((4,6-bis(dimethylamino)-1,3,5-triazin-2-yl)methylamino)methanol |
| pentamethylmonomethylolmelamine |
| methanol, ((4,6-bis(dimethylamino)-s-triazin-2-yl)methylamino)- |
| [[4,6-bis(dimethylamino)-1,3,5-triazin-2-yl]-methylamino]methanol |
| unii-s85c8w1eww |
| 16269-01-5 |
| 5-26-09-00141 (beilstein handbook reference) |
| s85c8w1eww , |
| SCHEMBL1309901 |
| n-hydroxymethylpentamethylmelamine |
| DTXSID90167434 |
| J-009966 |
| hydroxymethylpentamethylmelamine |
| 1-((4,6-bis(dimethylamino)-1,3,5-triazin-2-yl)methylamino)methanol |
| n-(hydroxymethyl)pentamethylmelamine |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Hexamethylmelamine (HMM) and a number of its derivatives are toxic to PC6 plasmacytoma cells in vitro." | ( In vitro cytotoxicity of the methylmelamines. Abel, G; Rutty, CJ, 1980) | 0.26 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic data were analyzed by an original method using a nonlinear cost function minimized by a simplex algorithm." | ( Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration. Abikhalil, F; Atassi, G; Dubois, J; Hanocq, M, 1986) | 0.27 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (83.33) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||